Targeted Therapy in Lung Cancer: Lessons Learned from Past Experiences

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Thoracic Oncology

• Publication date

  2011-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/01.JTO.0000407558.38416.c5PMID 22005531
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• JAK2 V617F positive essential thrombocythemia developing in a patient with CD5⁻ chronic lymphocytic leukemia.

  2012cited by this paper
• High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.

  2012cited by this paper
• Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells

  2011cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel in Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer

  2011cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.

  2011cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

  2011cited by this paper
• Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

  2011cited by this paper
• Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

  2011cited by this paper
• A Novel Mode of Protein Kinase Inhibition Exploiting Hydrophobic Motifs of Autoinhibited Kinases

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

  2011cited by this paper
• Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

  2011cited by this paper
• Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

  2011cited by this paper
• Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

  2011cited by this paper
• Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

  2011cited by this paper
• A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.

  2010cited by this paper
• Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

  2010cited by this paper
• Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs

  2010cited by this paper
• MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.

  2010cited by this paper
• Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.

  2010cited by this paper
• Resistance May Not Be Futile: microRNA Biomarkers for Chemoresistance and Potential Therapeutics

  2010cited by this paper
• Combined Analysis of Estrogen Receptor β-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor Outcome

  2010cited by this paper
• Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

  2010cited by this paper
• Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

  2010cited by this paper
• EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma

  2010cited by this paper
• A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

  2010cited by this paper
• Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

  2010cited by this paper
• Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

  2010cited by this paper
• Targeting the dynamic HSP90 complex in cancer

  2010cited by this paper
• A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC.

  2010cited by this paper
• Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors

  2010cited by this paper
• Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma: Preclinical Rationale and Clinical Trials

  2010cited by this paper
• Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Stereotactic body radiation therapy for inoperable early stage lung cancer.

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors

  2010cited by this paper
• ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer.

  2010cited by this paper
• Shared and separate functions of polo-like kinases and aurora kinases in cancer

  2010cited by this paper
• Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.

  2010cited by this paper
• The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer

  2010cited by this paper
• IAP antagonists: promising candidates for cancer therapy.

  2010cited by this paper
• INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect

  2010cited by this paper
• EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation*

  2010cited by this paper
• Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer.

  2010cited by this paper
• Vorinostat increases carboplatin and paclitaxel activity in non‐small cell lung cancer cells

  2010cited by this paper
• A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC.

  2010cited by this paper
• 412 BMS-754807, an oral dual IGF-1R/insulin receptor (IR) inhibitor: initial results from a Phase 1 dose- and schedule-finding study in combination with carboplatin/paclitaxel in subjects with solid tumors

  2010cited by this paper
• Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).

  2010cited by this paper
• Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors.

  2010cited by this paper
• A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.

  2010cited by this paper
• Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors.

  2010cited by this paper
• First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

  2010cited by this paper
• Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406.

  2010cited by this paper
• Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase.

  2010cited by this paper
• Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial

  2010cited by this paper
• The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets.

  2010cited by this paper
• Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.

  2010cited by this paper
• Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.

  2010cited by this paper
• Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

  2010cited by this paper
• GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.

  2010cited by this paper
• Estrogen Plus Progestin and Lung Cancer in Postmenopausal Women

  2010cited by this paper
• Hunting the Hedgehog Pathway

  2010cited by this paper
• Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells

  2009cited by this paper
• Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.

  2009cited by this paper
• Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies

  2009cited by this paper
• Kinesin motor proteins as targets for cancer therapy

  2009cited by this paper
• Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.

  2009cited by this paper
• Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer.

  2009cited by this paper
• Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

  2009cited by this paper
• SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients.

  2009cited by this paper
• X Chromosome-linked Inhibitor of Apoptosis Regulates Cell Death Induction by Proapoptotic Receptor Agonists

  2009cited by this paper
• Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.

  2009cited by this paper
• A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST).

  2009cited by this paper
• The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

  2009cited by this paper
• Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer

  2009cited by this paper
• Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

  2009cited by this paper
• Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

  2009cited by this paper
• Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

  2009cited by this paper
• Alterations of the Notch pathway in lung cancer

  2009cited by this paper
• Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179.

  2009cited by this paper
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

  2008cited by this paper
• Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).

  2008cited by this paper
• Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

  2008cited by this paper
• Drug development of MET inhibitors: targeting oncogene addiction and expedience

  2008cited by this paper
• Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.

  2008cited by this paper
• Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.

  2008cited by this paper
• Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2

  2008cited by this paper
• Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.

  2008cited by this paper
• Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer

  2008cited by this paper

• c-MET in Head and Neck Squamous Cell Carcinoma

  2018cites this paper
• Targeted Therapies for Lung Cancer

  2018cites this paper
• Pathology and Molecular Pathology of Lung Cancer

  2017cites this paper
• Surfactant-based drug delivery systems for treating drug-resistant lung cancer

  2016cites this paper
• Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

  2015cites this paper
• Aerosolized Medications for Gene and Peptide Therapy

  2015cites this paper
• Efficacy of a Magnetic Drug Delivery System and Development of an Orthotopic Lung Tumor Imaging Model

  2015cites this paper
• Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.

  2014cites this paper
• The Role of HGF/c-MET in Head and Neck Squamous Cell Carcinoma

  2014cites this paper
• Inhaled chemotherapy in lung cancer: future concept of nanomedicine

  2012cites this paper